IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v14y2023i1d10.1038_s41467-023-37381-4.html
   My bibliography  Save this article

Targeting C/EBPα overcomes primary resistance and improves the efficacy of FLT3 inhibitors in acute myeloid leukaemia

Author

Listed:
  • Hanlin Wang

    (Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Fudan University
    University of Chinese Academy of Sciences)

  • Guanghao Luo

    (Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    University of Chinese Academy of Sciences
    University of Chinese Academy of Sciences)

  • Xiaobei Hu

    (Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Chinese Academy of Sciences)

  • Gaoya Xu

    (Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Nanjing University of Chinese Medicine)

  • Tao Wang

    (Naval Medical University)

  • Minmin Liu

    (Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Jiangnan University)

  • Xiaohui Qiu

    (Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Chinese Academy of Sciences)

  • Jianan Li

    (Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Nanjing University of Chinese Medicine)

  • Jingfeng Fu

    (Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    University of Chinese Academy of Sciences)

  • Bo Feng

    (Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Shenyang Pharmaceutical University)

  • Yutong Tu

    (Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    University of Chinese Academy of Sciences)

  • Weijuan Kan

    (Shanghai Institute of Materia Medica, Chinese Academy of Sciences)

  • Chang Wang

    (Shanghai Institute of Materia Medica, Chinese Academy of Sciences)

  • Ran Xu

    (Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Nanjing University of Chinese Medicine)

  • Yubo Zhou

    (Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    University of Chinese Academy of Sciences
    Chinese Academy of Sciences
    Nanjing University of Chinese Medicine)

  • Jianmin Yang

    (Naval Medical University)

  • Jia Li

    (Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Fudan University
    University of Chinese Academy of Sciences
    University of Chinese Academy of Sciences)

Abstract

The outcomes of FLT3-ITD acute myeloid leukaemia (AML) have been improved since the approval of FLT3 inhibitors (FLT3i). However, approximately 30-50% of patients exhibit primary resistance (PR) to FLT3i with poorly defined mechanisms, posing a pressing clinical unmet need. Here, we identify C/EBPα activation as a top PR feature by analyzing data from primary AML patient samples in Vizome. C/EBPα activation limit FLT3i efficacy, while its inactivation synergistically enhances FLT3i action in cellular and female animal models. We then perform an in silico screen and identify that guanfacine, an antihypertensive medication, mimics C/EBPα inactivation. Furthermore, guanfacine exerts a synergistic effect with FLT3i in vitro and in vivo. Finally, we ascertain the role of C/EBPα activation in PR in an independent cohort of FLT3-ITD patients. These findings highlight C/EBPα activation as a targetable PR mechanism and support clinical studies aimed at testing the combination of guanfacine with FLT3i in overcoming PR and enhancing the efficacy of FLT3i therapy.

Suggested Citation

  • Hanlin Wang & Guanghao Luo & Xiaobei Hu & Gaoya Xu & Tao Wang & Minmin Liu & Xiaohui Qiu & Jianan Li & Jingfeng Fu & Bo Feng & Yutong Tu & Weijuan Kan & Chang Wang & Ran Xu & Yubo Zhou & Jianmin Yang , 2023. "Targeting C/EBPα overcomes primary resistance and improves the efficacy of FLT3 inhibitors in acute myeloid leukaemia," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    • Handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-37381-4
    DOI: 10.1038/s41467-023-37381-4
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-023-37381-4
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-023-37381-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Arvind Singh Mer & Emily M. Heath & Seyed Ali Madani Tonekaboni & Nergiz Dogan-Artun & Sisira Kadambat Nair & Alex Murison & Laura Garcia-Prat & Liran Shlush & Rose Hurren & Veronique Voisin & Gary D., 2021. "Biological and therapeutic implications of a unique subtype of NPM1 mutated AML," Nature Communications, Nature, vol. 12(1), pages 1-13, December.
    2. Jeffrey W. Tyner & Cristina E. Tognon & Daniel Bottomly & Beth Wilmot & Stephen E. Kurtz & Samantha L. Savage & Nicola Long & Anna Reister Schultz & Elie Traer & Melissa Abel & Anupriya Agarwal & Auro, 2018. "Functional genomic landscape of acute myeloid leukaemia," Nature, Nature, vol. 562(7728), pages 526-531, October.
    3. Haijiao Zhang & Samantha Savage & Anna Reister Schultz & Daniel Bottomly & Libbey White & Erik Segerdell & Beth Wilmot & Shannon K. McWeeney & Christopher A. Eide & Tamilla Nechiporuk & Amy Carlos & R, 2019. "Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms," Nature Communications, Nature, vol. 10(1), pages 1-13, December.
    4. Catherine C. Smith & Qi Wang & Chen-Shan Chin & Sara Salerno & Lauren E. Damon & Mark J. Levis & Alexander E. Perl & Kevin J. Travers & Susana Wang & Jeremy P. Hunt & Patrick P. Zarrinkar & Eric E. Sc, 2012. "Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia," Nature, Nature, vol. 485(7397), pages 260-263, May.
    5. Curtis R. Chong & David J. Sullivan, 2007. "New uses for old drugs," Nature, Nature, vol. 448(7154), pages 645-646, August.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Sternitzke, Christian, 2013. "An exploratory analysis of patent fencing in pharmaceuticals: The case of PDE5 inhibitors," Research Policy, Elsevier, vol. 42(2), pages 542-551.
    2. Elizabeth Heyes & Anna S. Wilhelmson & Anne Wenzel & Gabriele Manhart & Thomas Eder & Mikkel B. Schuster & Edwin Rzepa & Sachin Pundhir & Teresa D’Altri & Anne-Katrine Frank & Coline Gentil & Jakob Wo, 2023. "TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    3. J. McClatchy & R. Strogantsev & E. Wolfe & H. Y. Lin & M. Mohammadhosseini & B. A. Davis & C. Eden & D. Goldman & W. H. Fleming & P. Conley & G. Wu & L. Cimmino & H. Mohammed & A. Agarwal, 2023. "Clonal hematopoiesis related TET2 loss-of-function impedes IL1β-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    4. Rebecca Anderson & Lance D. Miller & Scott Isom & Jeff W. Chou & Kristin M. Pladna & Nathaniel J. Schramm & Leslie R. Ellis & Dianna S. Howard & Rupali R. Bhave & Megan Manuel & Sarah Dralle & Susan L, 2022. "Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia," Nature Communications, Nature, vol. 13(1), pages 1-13, December.
    5. Aditi Chattopadhyay & Madhavi K. Ganapathiraju, 2017. "Demonstration Study: A Protocol to Combine Online Tools and Databases for Identifying Potentially Repurposable Drugs," Data, MDPI, vol. 2(2), pages 1-11, May.
    6. Bofei Wang & Patrick K. Reville & Mhd Yousuf Yassouf & Fatima Z. Jelloul & Christopher Ly & Poonam N. Desai & Zhe Wang & Pamella Borges & Ivo Veletic & Enes Dasdemir & Jared K. Burks & Guilin Tang & S, 2024. "Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    7. David Wang & Mathieu Quesnel-Vallieres & San Jewell & Moein Elzubeir & Kristen Lynch & Andrei Thomas-Tikhonenko & Yoseph Barash, 2023. "A Bayesian model for unsupervised detection of RNA splicing based subtypes in cancers," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    8. Mengyun Yang & Huimin Luo & Yaohang Li & Fang-Xiang Wu & Jianxin Wang, 2019. "Overlap matrix completion for predicting drug-associated indications," PLOS Computational Biology, Public Library of Science, vol. 15(12), pages 1-21, December.
    9. Keith Woodley & Laura S. Dillingh & George Giotopoulos & Pedro Madrigal & Kevin M. Rattigan & Céline Philippe & Vilma Dembitz & Aoife M. S. Magee & Ryan Asby & Louie N. van de Lagemaat & Christopher M, 2023. "Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death," Nature Communications, Nature, vol. 14(1), pages 1-19, December.
    10. Matteo Maria Naldini & Gabriele Casirati & Matteo Barcella & Paola Maria Vittoria Rancoita & Andrea Cosentino & Carolina Caserta & Francesca Pavesi & Erika Zonari & Giacomo Desantis & Diego Gilioli & , 2023. "Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia," Nature Communications, Nature, vol. 14(1), pages 1-20, December.
    11. Mahmoud A. Bassal & Saumya E. Samaraweera & Kelly Lim & Brooks A. Benard & Sheree Bailey & Satinder Kaur & Paul Leo & John Toubia & Chloe Thompson-Peach & Tran Nguyen & Kyaw Ze Ya Maung & Debora A. Ca, 2022. "Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    12. Rebekka Wegmann & Lorenz Bankel & Yasmin Festl & Kate Lau & Sohyon Lee & Fabian Arnold & Valentina Cappelletti & Aaron Fehr & Paola Picotti & Konstantin J. Dedes & Daniel Franzen & Daniela Lenggenhage, 2024. "Molecular and functional landscape of malignant serous effusions for precision oncology," Nature Communications, Nature, vol. 15(1), pages 1-21, December.
    13. Tea Pemovska & Johannes W. Bigenzahn & Ismet Srndic & Alexander Lercher & Andreas Bergthaler & Adrián César-Razquin & Felix Kartnig & Christoph Kornauth & Peter Valent & Philipp B. Staber & Giulio Sup, 2021. "Metabolic drug survey highlights cancer cell dependencies and vulnerabilities," Nature Communications, Nature, vol. 12(1), pages 1-19, December.
    14. Sternitzke, Christian, 2010. "Knowledge sources, patent protection, and commercialization of pharmaceutical innovations," Research Policy, Elsevier, vol. 39(6), pages 810-821, July.
    15. Irati Macaya & Marta Roman & Connor Welch & Rodrigo Entrialgo-Cadierno & Marina Salmon & Alba Santos & Iker Feliu & Joanna Kovalski & Ines Lopez & Maria Rodriguez-Remirez & Sara Palomino-Echeverria & , 2023. "Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer," Nature Communications, Nature, vol. 14(1), pages 1-19, December.
    16. Tariq Kewan & Arda Durmaz & Waled Bahaj & Carmelo Gurnari & Laila Terkawi & Hussein Awada & Olisaemeka D. Ogbue & Ramsha Ahmed & Simona Pagliuca & Hassan Awada & Yasuo Kubota & Minako Mori & Ben Ponvi, 2023. "Molecular patterns identify distinct subclasses of myeloid neoplasia," Nature Communications, Nature, vol. 14(1), pages 1-10, December.
    17. Ravi K Patel & Mark C Weir & Kexin Shen & Daniel Snyder & Vaughn S Cooper & Thomas E Smithgall, 2019. "Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance," PLOS ONE, Public Library of Science, vol. 14(12), pages 1-29, December.
    18. Mohieddin Jafari & Mehdi Mirzaie & Jie Bao & Farnaz Barneh & Shuyu Zheng & Johanna Eriksson & Caroline A. Heckman & Jing Tang, 2022. "Bipartite network models to design combination therapies in acute myeloid leukaemia," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    19. Matteo Marchesini & Andrea Gherli & Elisa Simoncini & Lucas Moron Dalla Tor & Anna Montanaro & Natthakan Thongon & Federica Vento & Chiara Liverani & Elisa Cerretani & Anna D’Antuono & Luca Pagliaro &, 2024. "Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML," Nature Communications, Nature, vol. 15(1), pages 1-22, December.
    20. W. Frank Lenoir & Micaela Morgado & Peter C. DeWeirdt & Megan McLaughlin & Audrey L. Griffith & Annabel K. Sangree & Marissa N. Feeley & Nazanin Esmaeili Anvar & Eiru Kim & Lori L. Bertolet & Medina C, 2021. "Discovery of putative tumor suppressors from CRISPR screens reveals rewired lipid metabolism in acute myeloid leukemia cells," Nature Communications, Nature, vol. 12(1), pages 1-15, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-37381-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.